Nexsen secures first strategic hospital partner in Asia

Australian-listed biotech firm Nexsen (ASX:NXN) has achieved a milestone in its international expansion, announcing a binding term sheet with GHK Hospital.

The collaboration establishes a framework for the clinical validation and commercialisation of Nexsen's rapid point-of-care diagnostic platform within a leading clinical environment.

GHK, a subsidiary of the $27 billion healthcare giant IHH Healthcare Berhad, operates the prestigious Gleneagles Hospital Hong Kong.

As a 500-bed multi-speciality private tertiary facility and teaching hospital for The University of Hong Kong, Gleneagles provides Nexsen with vital access to specialist clinicians and diverse patient populations.

The partnership is a cornerstone of Nexsen’s broader Asia-Pacific strategy, arriving alongside a HK$6 million IGNITE Grant to establish dedicated R&D facilities in Hong Kong.

Nexsen Managing Director Mark Muzzin emphasised that the agreement provides a "critical bridge" between product development and real-world adoption, allowing the company to refine its diagnostics in a high-pressure hospital workflow.

Beyond immediate validation, the deal opens doors for joint R&D and the co-development of new diagnostic products targeting unmet clinical needs.

The move is further bolstered by the establishment of the UM-Nexsen Joint Research Facility in Malaysia, solidifying Nexsen’s regional footprint.

At the time of reporting, Nexsen's share price was $0.22.